



ASX ANNOUNCEMENT

9 April 2020

Business Update – COVID-19

IDT Australia Limited (ASX: IDT) provides the following update in regards to the COVID-19 pandemic and the Company's current and future business operations.

At the request of the Australian Government, IDT has been asked to assist with certain COVID-19 response activities. To this end IDT's GMP pharmaceutical manufacturing facilities and laboratory remain fully operational and business operations continue without disruption.

Since the emergence of COVID-19, IDT has implemented a range of measures designed to protect the health and safety of our employees whilst ensuring continuity of business operations. As the COVID-19 situation evolves IDT will continue to respond in accordance with current best practice.

Strict controls have been put in place to protect employees and support them to perform their roles in a safe and secure way. For example, the health of all employees is monitored on a daily basis, increased cleaning and hygiene practices have been put in place, social distancing protocols are strictly enforced, all travel has been cancelled, internal meetings have been minimised and are conducted virtually wherever possible, external meetings are conducted virtually and onsite visitors are restricted to only business essential site services. Working from home arrangements have been implemented where possible.

The Company continues to closely manage costs and our revenues are presently tracking in-line with budget as we push towards profitability. Continuity planning is in place across the business to maximise our ability to continue to function and to respond to challenges presented by COVID-19. We thank our staff for their exceptional dedication and commitment over this period.

Ends.../

IDT

Authorised by the Board of Directors of IDT Australia Limited.

For further information please contact:

Dr David Sparling

Chief Executive Officer - IDT Australia Limited

+61 303 9801 8888

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.